Full-Time

Business Systems Analyst

Manufacturing Applications

Updated on 8/23/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Bachelor's, Master's

Category
Business & Strategy (1)
Required Skills
Agile
ERP
Software Testing
Product Management
JIRA
Confluence

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A Bachelor's or Master's degree in Information Systems, Engineering, Supply Chain, Operations Management, or a related field is required.
  • Relevant experience in business systems analysis, product analysis, or functional application delivery for enterprise or manufacturing applications is required.
  • Strong experience leading requirements gathering, process mapping, story writing, acceptance criteria definition, and stakeholder alignment is required.
  • Hands-on experience with Agile delivery models, JIRA, Confluence, sprint planning, backlog management, and cross-functional collaboration is required.
  • Experience coordinating user acceptance testing, regression testing, defect management, and release readiness activities across business and technical teams is required.
  • Ability to translate plant operations needs into clear functional requirements for developers, solution architects, and external vendors is required.
  • Working knowledge of manufacturing scheduling, planning, or operations workflows, including the sequencing of production activities, equipment, and process steps in a plant environment, is required.
  • Familiarity with enterprise integrations and data dependencies across manufacturing and business systems is required.
  • Ability to manage multiple concurrent workstreams while maintaining traceability from business requirements through testing and release readiness is required.
  • Nine to twelve years of experience in Information Systems, Engineering, Supply Chain, Operations Management, or a related field is required.
Responsibilities
  • Lead requirements elicitation and process discovery sessions with site subject-matter experts and business stakeholders across the manufacturing scheduling and adjacent operations application portfolio.
  • Translate business needs into user stories, acceptance criteria, process flows, and prioritized backlog items for development and vendor teams, while identifying automation opportunities.
  • Partner with product owners, project managers, and delivery teams to maintain and prioritize the product backlog and support sprint planning, backlog grooming, demos, and defect triage.
  • Assess enhancement requests and solution options with technical leads and vendors, including feasibility, business impact, rollout sequencing, and dependency management.
  • Support application sustainment, enhancement, and lifecycle improvements across production scheduling applications used at multiple manufacturing sites.
  • Coordinate requirements and testing for changes involving upstream and downstream manufacturing systems, data flows, and planning integrations.
  • Document current-state and future-state workflows, business rules, master or reference data needs, and application behavior required to scale tools to new plants or use cases.
  • Create and maintain business requirements, process documentation, test artifacts, training materials, and release documentation with traceability to business outcomes.
  • Develop test plans, user acceptance testing scenarios, and regression test cases for each sprint or release, and coordinate execution with subject-matter experts.
  • Manage defect intake, clarify business impact, and follow up on resolution with development teams and vendors.
  • Support release readiness activities including stakeholder alignment, access enablement, communications, production cutover coordination, and adoption planning.
  • Identify opportunities to reduce manual scheduling effort, improve data quality, standardize decision-making, and retire legacy spreadsheet-driven or manual planning workflows.
Desired Qualifications
  • Background supporting finite scheduling, production planning, plant execution, predictive maintenance, or related operations processes is preferred.
  • Direct experience with manufacturing scheduling software, including SAP PP/DS or similar platforms, is helpful.
  • Experience with comparable manufacturing scheduling or operational platforms is a plus.
  • Previous manufacturing execution system or related execution-system experience is a plus.
  • Experience supporting manufacturing application scale-out, site onboarding, or major enterprise resource planning or upstream platform changes is a plus.
  • Experience in biotech, pharmaceutical, or other regulated manufacturing environments is desirable.
  • Experience producing training materials, job aids, and change-management content for end users and site teams is desirable.
  • Business analysis, Agile, Scaled Agile Framework, or product management certifications are a plus.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $10.1 billion, up 10%, and guidance rose to $39.4 billion.
  • Repatha, Evenity, and Uplizna surged 37%, 38%, and 90% in Q2 2026.
  • Amgen presented Repatha VESALIUS-CV data for ESC August 2026, expanding cardiovascular adoption.

What critics are saying

  • FDA proposed withdrawing Tavneos on April 27, 2026; EMA echoed revocation on June 26.
  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy franchise.
  • Harbour BioMed won a June 2026 willful patent verdict; MariTide failure would crush growth.

What makes Amgen unique

  • Amgen’s portfolio spans cardiovascular, bone, immunology, oncology, and biosimilars.
  • MariTide targets monthly or less frequent obesity dosing, unlike weekly GLP-1 rivals.
  • Amgen runs seven research labs plus Hyderabad’s 2027 science and innovation center.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.

PR Newswire
Aug 12th, 2026
Amgen to open new science and innovation centre in Hyderabad's Genome Valley

Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.

Yahoo Finance
Aug 9th, 2026
Amgen fair value rises to $372 after Q2 beat sparks analyst target hikes to $450

Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.

Yahoo Finance
Aug 5th, 2026
Amgen beats Q2 forecast with $10.05B revenue, raises 2026 outlook despite obesity drug setback

Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.